EMA confirms recommendation for non-renewal of authorisation of multiple myeloma medicine Blenrep

View source ↗

Summary

EU CHMP confirmed recommendation not to renew the conditional marketing authorisation for Blenrep (belantamab mafodotin) due to lack of confirmed effectiveness …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)

Snippet

EMA’s human medicines committee (CHMP) has confirmed its initial recommendation to not renew the conditional marketing authorisation for Blenrep (belantamab mafodotin) because recent data did not confirm its effectiveness; the benefits of Blenrep are therefore considered to no longer outweigh its risks.